Skip to main content

Table 2 Pathological response rate

From: Randomized phase II study comparing the efficacy and safety of SOX versus mFOLFOX6 as neoadjuvant chemotherapy without radiotherapy for locally advanced rectal cancer (KSCC1301)

  SOX arm mFOLFOX6 arm Total
  n=53 (%) n=48 (%) n=101 (%)
Grade 0 6 (11.3) 5 (10.4) 11 (10.9)
Grade 1a 24 (45.3) 22 (45.8) 46 (45.6)
Grade 1b 12 (22.6) 8 (16.7) 20 (19.8)
Grade 2 8 (15.1) 12 (25.0) 20 (19.8)
Grade 3 2 (3.8) 1 (2.1) 3 (3.0)
Unknown 1 (1.9) 0 (0.0) 1 (1.0)
  1. SOX: S-1 and oxaliplatin, mFOLFOX6: folinic acid, 5-FU, and oxaliplatin